Skip to main content
. 2021 Jan 8;13(1):174. doi: 10.3390/nu13010174

Figure 1.

Figure 1

(A) cholecystokinin (CCK), (B) active glucagon-like peptide-1 (aGLP-1), (C) peptide tyrosine tyrosine (PYY), (D) glucose-dependent insulinotropic peptide (GIP), (E) motilin, and (F) dose–response evaluation. Data are expressed as mean ± SEM, absolute values are reported. N = 12 (5 men and 7 women). Statistical tests: Linear mixed-effects modeling followed by Šidak post-hoc test in case of overall significance. Results of the statistical analysis are shown in Table 1.